XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:XOMAP • US98419J3059

25.85 USD
-0.2 (-0.77%)
At close: Feb 10, 2026
25.5 USD
-0.35 (-1.35%)
After Hours: 2/3/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

XOMAP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. There are concerns on the financial health of XOMAP while its profitability can be described as average. XOMAP is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • XOMAP had positive earnings in the past year.
  • XOMAP had a positive operating cash flow in the past year.
  • In multiple years XOMAP reported negative net income over the last 5 years.
  • In multiple years XOMAP reported negative operating cash flow during the last 5 years.
XOMAP Yearly Net Income VS EBIT VS OCF VS FCFXOMAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • With an excellent Return On Assets value of 3.75%, XOMAP belongs to the best of the industry, outperforming 89.67% of the companies in the same industry.
  • XOMAP's Return On Equity of 9.14% is amongst the best of the industry. XOMAP outperforms 92.35% of its industry peers.
  • XOMAP's Return On Invested Capital of 3.31% is amongst the best of the industry. XOMAP outperforms 90.44% of its industry peers.
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROIC 3.31%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAP Yearly ROA, ROE, ROICXOMAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • The Profit Margin of XOMAP (20.96%) is better than 93.50% of its industry peers.
  • XOMAP's Operating Margin of 20.92% is amongst the best of the industry. XOMAP outperforms 95.03% of its industry peers.
Industry RankSector Rank
OM 20.92%
PM (TTM) 20.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAP Yearly Profit, Operating, Gross MarginsXOMAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMAP is destroying value.
  • XOMAP has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for XOMAP has been increased compared to 5 years ago.
  • The debt/assets ratio for XOMAP is higher compared to a year ago.
XOMAP Yearly Shares OutstandingXOMAP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAP Yearly Total Debt VS Total AssetsXOMAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • XOMAP has an Altman-Z score of -4.54. This is a bad value and indicates that XOMAP is not financially healthy and even has some risk of bankruptcy.
  • XOMAP has a Altman-Z score (-4.54) which is comparable to the rest of the industry.
  • XOMAP has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMAP is somewhat dependend on debt financing.
  • The Debt to Equity ratio of XOMAP (0.87) is worse than 73.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z -4.54
ROIC/WACC0.26
WACC12.59%
XOMAP Yearly LT Debt VS Equity VS FCFXOMAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.91 indicates that XOMAP has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.91, XOMAP perfoms like the industry average, outperforming 47.04% of the companies in the same industry.
  • A Quick Ratio of 3.91 indicates that XOMAP has no problem at all paying its short term obligations.
  • XOMAP has a Quick ratio (3.91) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.91
XOMAP Yearly Current Assets VS Current LiabilitesXOMAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • The Revenue has grown by 103.96% in the past year. This is a very strong growth!
  • XOMAP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%

3.2 Future

  • The Earnings Per Share is expected to grow by 37.32% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, XOMAP will show a very strong growth in Revenue. The Revenue will grow by 41.64% on average per year.
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAP Yearly Revenue VS EstimatesXOMAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XOMAP Yearly EPS VS EstimatesXOMAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • XOMAP is valuated quite expensively with a Price/Earnings ratio of 34.47.
  • Based on the Price/Earnings ratio, XOMAP is valued cheaply inside the industry as 92.16% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 28.03. XOMAP is valued slightly more expensive when compared to this.
  • A Price/Forward Earnings ratio of 82.22 indicates a quite expensive valuation of XOMAP.
  • XOMAP's Price/Forward Earnings ratio is rather cheap when compared to the industry. XOMAP is cheaper than 88.15% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of XOMAP to the average of the S&P500 Index (27.97), we can say XOMAP is valued expensively.
Industry RankSector Rank
PE 34.47
Fwd PE 82.22
XOMAP Price Earnings VS Forward Price EarningsXOMAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XOMAP indicates a rather cheap valuation: XOMAP is cheaper than 92.35% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 31.33
XOMAP Per share dataXOMAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • XOMAP's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y37.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • XOMAP has a Yearly Dividend Yield of 8.31%, which is a nice return.
  • XOMAP's Dividend Yield is rather good when compared to the industry average which is at 1.14. XOMAP pays more dividend than 99.62% of the companies in the same industry.
  • XOMAP's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 8.31%

5.2 History

  • XOMAP has been paying a dividend for over 5 years, so it has already some track record.
  • XOMAP has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAP Yearly Dividends per shareXOMAP Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • XOMAP pays out 55.43% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP55.43%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
XOMAP Yearly Income VS Free CF VS DividendXOMAP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M
XOMAP Dividend Payout.XOMAP Dividend Payout, showing the Payout Ratio.XOMAP Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

XOMA ROYALTY CORP - XOMA 8 5/8 PERP

NASDAQ:XOMAP (2/10/2026, 8:00:02 PM)

After market: 25.5 -0.35 (-1.35%)

25.85

-0.2 (-0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-05
Inst Owners67.66%
Inst Owner ChangeN/A
Ins Owners1.79%
Ins Owner ChangeN/A
Market Cap320.02M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts84
Price Target64.7 (150.29%)
Short Float %0.02%
Short Ratio1.43
Dividend
Industry RankSector Rank
Dividend Yield 8.31%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years3
Ex-Date01-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)-6.01%
PT rev (3m)20.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-100.88%
EPS NY rev (1m)7.34%
EPS NY rev (3m)115.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.15%
Valuation
Industry RankSector Rank
PE 34.47
Fwd PE 82.22
P/S 6.79
P/FCF N/A
P/OCF 58.52
P/B 2.96
P/tB 5.05
EV/EBITDA 31.33
EPS(TTM)0.75
EY2.9%
EPS(NY)0.31
Fwd EY1.22%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.71%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.22
PEG (5Y)N/A
Graham Number12.13
Profitability
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROCE 4.2%
ROIC 3.31%
ROICexc 4.14%
ROICexgc 5.42%
OM 20.92%
PM (TTM) 20.96%
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA 7.77
Cap/Depr 880.03%
Cap/Sales 42.84%
Interest Coverage 0.83
Cash Conversion 45.03%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.91
Altman-Z -4.54
F-Score6
WACC12.59%
ROIC/WACC0.26
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.62%
Revenue Next 2Y49.83%
Revenue Next 3Y34.18%
Revenue Next 5Y41.64%
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.59%
EBIT Next 3Y49.29%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A

XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ

What is the ChartMill fundamental rating of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) stock?

ChartMill assigns a fundamental rating of 5 / 10 to XOMAP.


Can you provide the valuation status for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?

ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP). This can be considered as Fairly Valued.


What is the profitability of XOMAP stock?

XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for XOMAP stock?

The Price/Earnings (PE) ratio for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 34.47 and the Price/Book (PB) ratio is 2.96.


Can you provide the financial health for XOMAP stock?

The financial health rating of XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 3 / 10.